

**PERTH, Australia, 1st December 2017:** Phylogica Limited (ASX:PYC) (**Phylogica** or the **Company**), submits an Appendix 3Z in relation to the retirement of Professor Paul Watt as a Director;

As announced to ASX on 21st November 2017, Professor Watt decided not to stand for re-election as a Director of the Company at the 2017 Annual General Meeting held on 24th November 2017.

Yours faithfully

Kevin Hart

**Company Secretary**

**ENDS**

For further information, please contact:

**INVESTORS**

Stephanie Unwin  
CEO  
[stephanieu@phylogica.com](mailto:stephanieu@phylogica.com)  
0411 132 287

**MEDIA**

Ben Walsh  
WE Buchan  
[bwalsh@buchanwe.com.au](mailto:bwalsh@buchanwe.com.au)  
0411 520 012

## About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug cargoes into cells, and the company's lead asset program has identified a phylomer which can inhibit Myc, a protein responsible for the regulation of cancer cell growth. The company has had collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and is currently working with Genentech.

---

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

[www.phylogica.com](http://www.phylogica.com)

**Phylogica Ltd**

ABN 48 098 391 961

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b> PHYLOGICA LIMITED
<b>ACN</b> 098 391 961

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	PAUL WATT
<b>Date of last notice</b>	26 October 2017
<b>Date that director ceased to be director</b>	24 November 2017

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>  4,044,123 Ordinary shares
--

+ See chapter 19 for defined terms.

## Appendix 3Z Final Director's Interest Notice

---

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> Note: Provide details of the circumstances giving rise to the relevant interest	<b>Number &amp; class of securities</b>
Paul Michael Watt & Maria Del Pilar Enriquez-Watt ATF The Brainchild Super Fund	10,473,074 Ordinary Shares
Maria Del Pilar Enriquez-Watt	10,000,000 Ordinary Shares 10,000,000 Unlisted options expiring 30 June 2018, nil exercise price.

### Part 3 – Director's interests in contracts

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>No. and class of securities to which interest relates</b>	N/A

---

+ See chapter 19 for defined terms.